Navigation Links
Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting

GENEVA, Switzerland, April 27, 2007 – Merck Serono S.A. (virt-x: SEO) and its partner Newron Pharmaceuticals S.p.A. (SWX: NWRN) announced today that Professor Fabrizio Stocchi, MD, PhD, will present the results of the first Phase III trial of safinamide as an adjunctive treatment to dopamine agonists (DA) in early Parkinson’s disease (PD) patients at the American Academy of Neurology 59th Annual Meeting to be held in Boston from 28 April to 5 May 2007.

The abstract entitled "Safinamide, a New Anti-Parkinson Agent is Effective and Well-Tolerated in Early PD Patients on a Stable Dose of a Single DA-Agonist: Results of a Randomized, International, Placebo-Controlled, Phase III Trial" was accepted for an oral presentation that is scheduled for Tuesday, May 1, 2007 at 3.45pm at Session S20: Movement Disorders: Essential Tremor and Medications for Parkinson’s Disease, at the Hynes Convention Center in Boston, MA, U.S.A.

Fabrizio Stocchi is a Professor of Neurology and Honorary Consultant at the IRCCS San Raffaele Rome, University "La Sapienza". He is Director of the Movement Disorders Centre and the Clinical Trial Center of the same institute.

In October 2006, Merck Serono and Newron signed a global development and commercialization agreement under which Newron has granted Merck Serono exclusive worldwide rights to develop, manufacture and commercialise safinamide in

Merck Serono 9 Chemin des Mines Corporate Media Relations Corporate Investor Relations 1202 Geneva Tel:+41 22 414 36 00 Tel:+41 22 414 36 01 Switzerland Media Relations, USA Investor Relations, USA www.merckserono.net Tel :+1 781 681 23 40 Tel:+1 781 681 25 52 News Release

Parkinson’s disease, Alzheimer’s disease, other cognitive disorders and Restless Leg Syndrome.

###
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
3. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
4. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
5. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/6/2008)...IPPENHAM, England, October 7 /PRNewswire-FirstCall... Index: 4565) and Vectura,Group plc ("Vectura"; LS...evaluating the efficacy, safety and tolerability o...uropean Respiratory Society (ERS) in Berlin,Germa...bromide), a novel,inhaled long-acting muscarinic a...
(Date:10/6/2008)... 6 /PRNewswire-USNewswire/ -- "A return to the use...opment is without scientific,justification," accor...rnatives to Laboratory Animals (ATLA). "An Assessm...earch" concludes that vaccine responses in,chimpan...d that claims of,chimpanzees, critical role and im...
(Date:10/6/2008)...video clips feature children, parents discussing c...ETHESDA, Md., Oct. 6 /PRNewswire-USNewswire/ -- Fr...rch in children saves lives and improves their,hea...al Institutes of,Health (NIH), "Children and Clini...es.nhlbi.nih.gov ), offers parents and health,care...
(Date:10/6/2008)...m Phase 3b Studies with Durezol Dosed Prior to Sur...Therapeutics, Inc., a,privately held ophthalmic-fo...hat Durezol(TM) (difluprednate ophthalmic emulsion...ich was approved by the U.S. Food and,Drug Adminis...icosteroid,indicated for the treatment of inflamma...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 1Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 2Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 3Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 4Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 1Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 2Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 3Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 4Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 5OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 1OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 2OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 3Latest Advances in Infection Prevention and Control to be Presented in Denver CO at Worlds Largest Annual Infection Prevention Conference June 15 19 20866 1
...rimary Endpoint of Improvement in Overall,Survival...rstCall/ --,Allos Therapeutics, Inc. today announc...otal Phase 3 study of Efaproxyn ,(efaproxiral) plu...th brain metastases originating from breast cancer... of demonstrating a,statistically significant impr...
...2007 /PRNewswire-FirstCall/ -- Anadys,Pharmaceutic...to,the discovery, development and commercializatio...s and cancer, announced today that it,has nominate...s an,orally-administered direct antiviral for the ...tion. , "We have identified a small-molecule, non-...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
(Date:10/6/2008)...de effects can affect length of stay, study says ,...Simple changes to hospital procedures can signific...e on opiates to relieve pain, a new study reveals.... 14 U.S. children,s hospitals, documented a 67 per...in relievers under these new procedures. , The...
(Date:10/6/2008)...ased resource designed to engage and educate viewe...ns including Health Savings Accounts (HSAs), Healt...ing Accounts (FSAs), has partnered with sister com...ices in concert with its existing direct-to-broker... MINNEAPOLIS (Business Wire EON) Oc...
(Date:10/6/2008)...eukemia Victim Ernie Davis, Is, Spokesperson for T...ght(R) Walk, WHI...s, a 1960s,football hero who was the first African...t of the new film from Universal Pictures, The Exp...ercame seemingly insurmountable,obstacles to becom...
(Date:10/6/2008)... Today, PARI Pharma GmbH will,unveil a prototype C...le,dose ampoules to control medication used in the...-dose ampoule that is required to operate the,nebu...ets an unmet need by,reducing the risk of using th...ying filling procedures, improving dose uniformity...
Breaking Medicine News(10 mins):Health News:Hospital Fixes Cut Opiate Errors in Kids 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 3Health News:Release of Universal Film The Express Draws Attention to Tragedy of Lives Cut Short by Blood Cancer 2Health News:PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference 2
...omen had about a 20 percent lower chance of develo... new research bolsters the theory that the female ...al cancer. Dr. Carlo La Vecchia, who led the s...uspected that estrogen in the pill could protect a...
...re is poorly controlled. Drugs and lifestyle modif...rtension) yet these measures are not being taken b...he Baylor School of Medicine, Houston, Texas, doct...00 adults over 25 and found that 27 per cent had h...
...anization for Scientific Research (NWO) discovered...tance to disease if they took extra zinc in additi..., zinc was largely ignored due to the difficulty i...Scientists now know that zinc deficiency leads to ...
...er these days, wonder premature memory loss is no... too much work causing lack of concentration, memo...erations in memory and neurotransmitters are found...nson's disease and Alzheimer's disease. // The fun...
Other Medicine News:
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance.
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy.
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu
Medicine Products: